FrancophonIA/ELRC3.0 huggingface dataset:
English: Consult the dosing table for the specific formulation (see relevant Summary of Product Characteristics).
Maltese: Ikkonsulta t-tabella taddożaġġ għall-formulazzjoni speċifika (ara s-Sommarju tal-Karatteristiċi tal-Prodott rilevanti).
English: SEDATIVES Benzodiazepines Midazolam
Maltese: Benzodiazepines
English: Table 3.
Maltese: Tabella 7:
English: Reversible elevations in indirect (unconjugated) bilirubin related to inhibition of UDP-glucuronosyl transferase (UGT) have occurred in patients receiving atazanavir (see section 4.8).
Maltese: Kien hemm livelli għolja riversibbli fil-bilirubin indirett (mhux konjugat) assoċjati ma' l-inibizzjoni tal-UDP-glucuronosil transferasi (UGT) f'pazjenti li ħadu atazanavir (ara sezzjoni 4.8).
English: Ritonavir is used as a booster of atazanavir pharmacokinetics (see sections 4.5 and 5.1).
Maltese: Ritonavir jingħata biex isaħħaħ il-qawwa farmakokinetika ta' atazanavir (ara sezzjonijiet 4.5 u 5.1).
English: Subjects with at least one functional CYP2C19 allele.
Maltese: Individwi b'tal-anqas allele CYP2C19 funzjonali wieħed.
English: Atazanavir Mylan 200 mg hard capsules are blue and greenish-blue opaque capsules with ‘MYLAN' over ‘AR200' printed in black ink on cap and body.
Maltese: Atazanavir Mylan 200 mg kapsuli ibsin huma kapsuli opaki ta' lewn blu u aħdar-blu, b''MYLAN' fuq ‘AR200' stampati b'linka sewda fuq l-għatu u l-korp.
English: How to store Atazanavir Mylan 6.
Maltese: Kif taħżen Atazanavir Mylan 6.
English: Atazanavir (without ritonavir) has been studied in adult patients with severe renal impairment (n=20), including those on haemodialysis, at multiple doses of 400 mg once daily.
Maltese: Atazanavir (mingħajr ritonavir) kien studjat f'pazjenti adulti b'indeboliment sever tal-kliewi (n=20), li jinkludu dawk fuq l-emodijalisi, f'dożi multipli ta' 400 mg darba kuljum.
English: Studies in humans and in vitro studies using human liver microsomes have demonstrated that atazanavir is principally metabolised by CYP3A4 isozyme to oxygenated metabolites.
Maltese: Minn studji fil-bniedem u minn studji in vitro fejn intużaw mikrosomi epatiċi umani sar magħruf li atazanavir ġie metabolizzat prinċipalment bl-iżożimu ta' CYP3A4 għal metaboliti ossiġenati.
English: • If tenofovir disoproxil or an H2-receptor antagonist is needed, a dose increase to atazanavir 400 mg with ritonavir 100 mg with TDM may be considered (see sections 4.6 and 5.2).
Maltese: Jekk ikun meħtieġ tenofovir disoproxil jew antagonista ta' riċettur ta' H2, tista' tiġi kkunsidrata żieda fid-doża ta' atazanavir 400 mg ma' ritonavir 100 mg b'TDM (ara sezzjonijiet 4.6 u 5.2).
English: The pharmacokinetic data from HIV-infected pregnant women receiving atazanavir capsules with ritonavir are presented in Table 8.
Maltese: It-tagħrif farmakokinetiku minn nisa tqal infettati bl-HIV li kienu qegħdin jirċievu kapsuli ta' atazanavir ma' ritonavir huwa ppreżentat fit-Tabella 8.
English: Withdrawal of ritonavir only under restrictive conditions
Maltese: L-irtirar ta' ritonavir biss taħt kundizzjonijiet restrittivi
English: , toxic skin eruptions a,b drug rash with eosinophilia and systemic symptoms (DRESS) syndrome a,b
Maltese: komuni: raxx; mhux komuni: eritema multiformea,b, eruzzjonijiet tossiċi tal-ġildaa,b, sindromu ta' raxx dovut għall-mediċina b'esinofilja u sintomi sistemiċi (DRESS - drug rash with eosinophilia and systemic symptoms)a,b, anġjoedemaa,
English: Cmin is concentration 24 hours post-dose.
Maltese: b Cmin hija konċentrazzjoni 24 siegħa wara d-doża.
English: HDPE bottle with polypropylene screw cap containing 60 capsules.
Maltese: FARMAĊEWTIKA U KONTENUT 60 kapsula iebsa.
English: 293 (n=14
Maltese: 293 (n=14b)
English: uncommon: dyspnoea
Maltese: mhux komuni: dispneja
English: Asymptomatic PR interval prolongation was more frequent in paediatric patients than adults.
Maltese: Prolongazzjoni asintomatika tal-intervall PR kienet aktar frekwenti f'pazjenti pedjatriċi milli fl-adulti.
English: Norethindrone Cmin ↑262% (↑157%
Maltese: Cmin ta' Norethindrone ↑262 %
English: Tenofovir disoproxil fumarate Cmax ↑34% (↑20% ↑51%)
Maltese: AUC ta' Tenofovir disoproxil fumarate ↑37% (↑30% ↑45%) Cmax ta' Tenofovir disoproxil fumarate ↑34% (↑20% ↑51%) Cmin ta' Tenofovir disoproxil fumarate ↑29% (↑21% ↑36%)
English: Table 2: Interactions between atazanavir and other medicinal products
Maltese: Tabella 2: Interazzjonijiet bejn atazanavir u prodotti mediċinali oħra Prodotti mediċinali skont ilqasam terapewtiku
English: Atazanavir Cmax ↑12% (↓33%
Maltese: Cmax ta' Atazanavir ↑12% (↓33%
English: Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse reactions.
Maltese: Pazjenti li jbatu minn epatite kronika B jew Ċ u kkurati b'taħlita ta' terapija antiretrovirali għandhom iktar riskju ta' reazzjonijiet avversi, epatiċi severi u potenzjalment fatali.
English: Three of 20 infants (15%) born to women treated with atazanavir/ritonavir 300/100 mg and four of 20 infants (20%) born to women treated with atazanavir/ritonavir 400/100 mg experienced grade 3-4 bilirubin.
Maltese: Tlieta mill-20 tarbija (15%) imwielda minn nisa kkurati b'atazanavir/ritonavir 300/100 mg u erbgħa minn 20 tarbija (20%) twieldu lil nisa kkurati bi atazanavir/ritonavir 400/100 mg esperjenzaw bilirubin ta' skala 3-4.
English: Atazanavir AUC ↑28% (↑16%
Maltese: AUC ta' Atazanavir ↑28% (↑16%
English: PULMONARY ARTERIAL HYPERTENSION PDE5 Inhibitors
Maltese: Inibituri tal-PDE5
English: Capsule shell cap 300 mg
Maltese: Kapsuli ta' 300 mg
English: NA NA NA
Maltese: • uġigħ ta' ras
English: The atazanavir/ritonavir arm showed similar (non-inferior) antiviral efficacy compared to the lopinavir/ritonavir arm, as assessed by the proportion of patients with HIV RNA < 50 copies/ml at week 48 (Table 5).
Maltese: Il-fergħa ta' atazanavir/ritonavir auriet effikaċja antivirali simili (mhux inferjuri) meta mqabbla mal-fergħa ta' lopinavir/ritonavir, kif evalwat mill-proporzjon ta' pazjenti b'HIV RNA < 50 kopji/ml f'ġimgħa 48: (Tabella 5).
English: Pravastatin is not metabolised by CYP3A4.
Maltese: Pravastatin mhuwiex metabolizzat minn CYP3A4.
English: Atazanavir Mylan 200 mg hard capsules atazanavir
Maltese: Atazanavir Mylan 200 mg kapsuli ibsin atazanavir
English: Atazanavir Mylan, co-administered with low dose ritonavir, is indicated for the treatment of HIV-1 infected adults and paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products (see section 4.2).
Maltese: Atazanavir Mylan, li jingħata flimkien ma' doża baxxa ta' ritonavir, huwa indikat bħala kura lil pazjenti adulti u pedjatriċi li għandhom 6 snin jew aktar infettati b'HIV-1 flimkien ma' prodotti mediċinali antiretrovirali oħra (ara sezzjoni 4.2).
English: 229 (n=14
Maltese: 229 (n=14b)
English: Mylan Hungary Kft H-2900 Komárom, Mylan utca 1 Hungary
Maltese: Komárom, Mylan utca 1 L-Ungerija
English: Atazanavir is metabolised principally by CYP3A4.
Maltese: Atazanavir huwa prinċipalment metabolizzat minn CYP3A4.
English: CD4 Mean Change from Baseline, cells/mm by Baseline Characteristic
Maltese: Bidla Medja mill-Linja Bażi, cells/mm3 Il-pazjenti kollha
English: - in patients with at least one functional CYP2C19 allele, close clinical monitoring for a loss of both voriconazole (clinical signs) and atazanavir (virologic response) efficacy is recommended.
Maltese: - f'pazjenti b'tal-anqas allele CYP2C19 wieħed, monitoraġġ kliniku mill-qrib għat-telf taleffikaċja kemm ta' voriconazole (sinjali kliniċi) u atazanavir (rispons viroloġiku) hu rakkomandat.
English: The combination of Atazanavir Mylan with atorvastatin is not recommended (see section 4.5).
Maltese: Il-kombinazzjoni ta' Atazanavir Mylan ma' atorvastatin mhijiex rakkomandata (ara sezzjoni 4.5).
English: ANTIBIOTICS Clarithromycin 500 mg twice daily
Maltese: ANTIBIJOTIĊI Clarithromycin 500 mg darbtejn kuljum (atazanavir 400 mg darba kuljum)
English: Midazolam and triazolam are extensively metabolised by CYP3A4.
Maltese: Midazolam u triazolam jiġu metabolizzati b'mod estensiv minn CYP3A4.
English: Treatment of overdose with atazanavir should consist of general supportive measures, including monitoring of vital signs and electrocardiogram (ECG), and observations of the patient's clinical status.
Maltese: Il-kura għal doża eċċessiva ta' atazanavir għandha tkun magħmula minn kull mezz ta' għajnuna, inkluż il-monitoraġġ ta' sinjali vitali u elettrokardjogramm (ECG), u osservazzjonijiet tal-kondizzjoni klinika tal-pazjent.
English: Atazanavir Cmin ↓23% (↓43% ↑2%)
Maltese: Cmin ta' Atazanavir ↓23% (↓43%
English: Study 045 is a randomised, multicenter trial comparing atazanavir /ritonavir (300/100 mg once daily) and atazanavir /saquinavir (400/1,200 mg once daily), to lopinavir + ritonavir (400/100 mg fixed dose combination twice daily), each in combination with tenofovir disoproxil fumarate (see sections 4.5 and 4.8) and one NRTI, in patients with virologic failure on two or more prior regimens containing at least one PI, NRTI, and NNRTI.
Maltese: Studju 045 huwa studju fuq bażi każwali, b'aktar minn ċentru wieħed, fuq bażi każwali li jqabbel atazanavir /ritonavir (300/100 mg darba kuljum) u atazanavir/saquinavir (400/1,200 mg darba kuljum, u ma' lopinavir + ritonavir (400/100 mg flimkien f'doża fissa kombinata, darbtejn kuljum), kull waħda flimkien ma' tenofovir disoproxil fumarate (ara sezzjonijiet 4.5 u 4.8) u NRTI wieħed, f' pazjenti li kellhom falliment viroloġiku f'żewġ kuri jew iżjed mogħtija qabel li kien fihom għallinqas PI, NRTI u NNRTI wieħed.
English: LIPID LOWERING AGENTS HMG- CoA reductase inhibitors Simvastatin
Maltese: Inibituri ta' HMG-CoA reductase
English: Both asymptomatic first-degree (23%) and second-degree (1%) atrioventricular block were reported in paediatric patients.
Maltese: Ġew irrappurtati kemm imblokk atrijoventrikulari tal-ewwel grad (23%) u tat-tieni grad (1%) f'pazjenti pedjatriċi.
English: Tel: +386 1 236 31 85
Maltese: GSP Proizvodi d.o.o. Tel: +386 1 236 31 85
English: uncommon: nephrolithiasis a, haematuria, proteinuria, pollakiuria, interstitial nephritis, chronic kidney disease a;
Maltese: Disturbi fil-kliewi u fis-sistema urinarja: mhux komuni: nefrolitjażia, ematurja, proteinurja, pollakurja; nefrite interstizjali, mard tal-kliewi kronikua rari: uġigħ fil-kliewi
English: Elbasvir 50 mg once daily (atazanavir 300 mg / ritonavir 100 mg once daily)
Maltese: Elbasvir 50 mg darba kuljum (atazanavir 300 mg / ritonavir 100 mg darba kuljum)
English: Mylan B.V., Dieselweg 25, 3752 LB Bunschoten, The Netherlands
Maltese: L-Ungerija Mylan B.V., Dieselweg 25, 3752 LB Bunschoten, L-Olanda Għal kull tagħrif dwar din il-mediċina, jekk jogħġbok ikkuntattja lir-rappreżentant lokali tad-Detentur tal-Awtorizzazzjoni għat-Tqegħid fis-Suq:
English: Atazanavir is primarily hepatically metabolised and increased plasma concentrations were observed in patients with hepatic impairment (see sections 4.2 and 4.3).
Maltese: Atazanavir huwa primarjament metabolizzat mill-fwied u żidiet fil-konċentrazzjoni tal-plażma ġew osservati f'pazjenti b'indeboliment tal-fwied (ara sezzjonijiet 4.2 u 4.3).
English: Reduced plasma concentrations of atazanavir may be the consequence of increased gastric pH if antacids, including buffered medicinal products, are administered with atazanavir.
Maltese: Il-konċentrazzjonijiet imnaqqsa ta' atazanavir fil-plażma jistgħu jkunu l-konsegwenza ta' żieda fil-pH gastriku jekk antaċidi, inklużi prodotti mediċinali buffered jingħataw ma' atazanavir.
English: The mechanism of interaction between atazanavir and tenofovir disoproxil fumarate is unknown.
Maltese: Ilmekkaniżmu ta' interazzjoni bejn atazanavir u tenofovir disoproxil fumarate mhuwiex magħruf.
English: Particular caution should be used when prescribing Atazanavir Mylan in association with medicinal products which have the potential to increase the QT interval and/or in patients with pre-existing risk factors (bradycardia, long congenital QT, electrolyte imbalances (see sections 4.8 and 5.3).
Maltese: Għandha tingħata attenzjoni partikulari meta Atazanavir Mylan ikun preskritt flimkien ma' prodotti mediċinali li jistgħu jżidu l-intervall QT u/jew f'pazjenti li diġà għandhom fatturi ta' riskju (bradikardja, QT konġenitali twila, żbilanċi ta' elettroliti (ara sezzjonijiet 4.8 u 5.3).
English: Among patients who received atazanavir 400 mg once daily or atazanavir 300 mg with ritonavir 100 mg once daily, the only adverse reactions of any severity reported very commonly with at least a possible relationship to regimens containing atazanavir and one or more NRTIs were nausea (20%), diarrhoea (10%), and jaundice (13%).
Maltese: Fost il-pazjenti li ħadu atazanavir 400 mg darba kuljum jew atazanavir 300 mg ma' ritonavir 100 mg darba kuljum, l-uniċi reazzjonijiet avversi ta' xi severità li ġew irrappurtati b'mod komuni ħafna li għall-inqas kien possibbli li kellhom x'jaqsmu mat-terapija li kienet tinkludi atazanavir u wieħed jew iktar NRTIs kienu nawsja (20%), dijarrea (10%) u suffejra (13%).
English: e)
Maltese: 3. LISTA
English: Ritonavir 100 mg once daily is used as a booster of atazanavir pharmacokinetics.
Maltese: Ritonavir 100 mg darba kuljum jintuża bħala booster talfarmakokinetika ta' atazanavir.
English: At baseline, 34% of patients were receiving a PI and 60% were receiving an NNRTI.
Maltese: Bħala linja bażi, 34% tal-pazjenti ħadu PI u 60% ħadu NNRTI.
English: Although this study presented some limitations (i.e., unbound drug concentrations not studied), results suggested that the atazanavir pharmacokinetic parameters were decreased by 30% to 50% in patients undergoing haemodialysis compared to patients with normal renal function.
Maltese: Għalkemm dan listudju kellu xi limitazzjonijiet (i.e., konċentrazzjonijiet ta' mediċina mhux imwaħħla ma kinux studjati), ir-riżultati ssuġġerew li l-parametri farmakokinetiċi ta' atazanavir tnaqqsu bi 30% sa 50% tal-pazjenti li kienu fuq l-emodijalisi meta mqabbel ma' pazjenti b'funzjoni normali tal-kliewi.
English: Magyarország Mylan EPD Kft
Maltese: Mylan Hungary Kft H-2900
English: Atazanavir Cmax ↔5% (↓17%
Maltese: Cmax ta' Atazanavir5 % (↓17%
English: If the combination of Atazanavir Mylan with a proton pump inhibitor is judged unavoidable, close clinical monitoring is recommended in combination with an increase in the dose of atazanavir to 400 mg with 100 mg of ritonavir; doses of proton pump inhibitors comparable to omeprazole 20 mg should not be exceeded.
Maltese: Jekk il-kombinazzjoni ta' Atazanavir Mylan ma' inibitur proton pump titqies bħala waħda inevitabbli, monitoraġġ kliniku mill-qrib huwa rakkomandat f'kombinazzjoni ma' żieda fid doża ta' atazanavir ta' 400 mg ma' 100 mg ta' ritonavir; id-dożi ta' inibituri proton pump komparabblima' omeprazole 20 mg ma għandhomx jinqabżu.
English: (400 mg/ 100 mg twice daily) n=123
Maltese: LPV/RTVc (400 mg/ 100 mg darbtejn kuljum) n=123
English: common: vomiting, diarrhoea, abdominal pain, nausea, dyspepsia; uncommon: pancreatitis, gastritis, abdominal distension, stomatitis aphthous, flatulence, dry mouth
Maltese: mhux komuni: pankreatite, gastrite, distensjoni addominali, stomatite aphthous, gass fl-istonku, ħalq xott
English: If withdrawal of ritonavir is medically warranted under restrictive conditions (see section 4.4), special attention should be given to atazanavir interactions that may differ in the absence of ritonavir (see information below Table 2).
Maltese: Jekk ikun hemm ġustifikazzjoni medika għall-irtirar ta' ritonavir taħt kundizzjonijiet restrittivi (ara sezzjoni 4.4), għandha tingħata attenzjoni speċjali lil interazzjonijiet ta' atazanavir li jistgħu jvarjaw fin-nuqqas ta' ritonavir (ara l-informazzjoni fit-Tabella 2 hawn taħt).
English: In clinical trials of antiretroviral treatment naive patients treated with unboosted atazanavir, the I50L substitution, sometimes in combination with an A71V change, is the signature resistance substitution for atazanavir.
Maltese: F'esperimenti kliniċi ta' pazjenti li qatt qabel ma ħadu kura antiretrovirali li ġew ittratati b'atazanavir mhux ibbustjat, is-sostituzzjoni I50L, kultant flimkien ma' bidla fl-A71V, hija sostituzzjoni ta' reżistenza firmatarja għal atazanavir.
English: common: fatigue; uncommon: chest pain, malaise, pyrexia, asthenia; rare: gait disturbance a These adverse reactions were identified through post-marketing surveillance, however, the frequencies were estimated from a statistical calculation based on the total number of patients exposed to atazanavir in randomised controlled and other available clinical trials (n = 2321).
Maltese: madankollu l-frekwenzi ġew stmati minn kalkolazzjoni statistika bbażata fuq in-numru totali ta' pazjenti esposti għal atazanavir fi provi kliniċi randomizzati u kkontrollati u fi provi kliniċi disponibbli oħrajn (n = 2,321).
English: Rash and associated syndromes
Maltese: Raxx u sindromi assoċjati
English: ANTINEOPLASTICS AND IMMUNOSUPRESSANTS Antineoplastics
Maltese: Antineoplastiċi
English: atazanavir AUC ↓ 35%
Maltese: AUC ta' Atazanavir2.3 %
English: Ritonavir may decrease plasma levels of phenytoin and/or phenobarbital due to CYP2C9 and
Maltese: Ritonavir jista' jnaqqas il-livelli ta' phenytoin u/jew ta' phenobarbital minħabba induzzjoni ta' CYP2C9 u ta' CYP2C19.
English: Asymptomatic first- and second-degree AV block was reported in paediatric patients (see section 4.8).
Maltese: Imblokk AV asintomatiku tal-ewwel u t-tieni grad kien irrapportat f'pazjenti pedjatriċi (ara sezzjoni 4.8).
English: Atazanavir Mylan 150 mg hard capsules
Maltese: Atazanavir Mylan 150 mg kapsuli ibsin
English: Electrocardiographic changes (sinus bradycardia, prolongation of PR interval, prolongation of QT interval, and prolongation of QRS complex) were observed only in an initial 2 week oral toxicity study performed in dogs.
Maltese: Bidliet elettrokardjografiċi (sinus bradycardia, titwil ta' l-intervall PR, titwil ta' l-intervall QT u titwil tal-kumpless QRS) kienu osservati biss fi studju inizjali tat-tossiċità orali ta' ġimagħtejn, li sar fil-klieb.
English: The mean half-life of atazanavir in hepatically impaired subjects was 12.1 hours compared to 6.4 hours in healthy subjects.
Maltese: Il-half-life medja ta' atazanavir f'individwi b'indeboliment tal-funzjoni epatika kienet ta' 12.1 sigħat meta mqabbla ma' 6.4 sigħat f'individwi b'saħħithom.
English: ATV/RTV with tenofovir disoproxil fumarate/emtricitabine (fixed dose 300 mg/200 mg tablets once daily).
Maltese: b ATV/RTV b'tenofvir/disoproxil fumarate/emtricitabine (doża fissa ta' pilloli 300 mg/200 mg darba kuljum), c LPV/RTV b'tenofvir/disoproxil fumarate/emtricitabine (doża fissa ta' pilloli ta' 300 mg/200 mg darba kuljum).
English: Through 48 weeks of treatment, the mean changes from baseline in HIV RNA levels for atazanavir + ritonavir and lopinavir + ritonavir were similar (non-inferior).
Maltese: HIV RNA għal atazanavir + ritonavir u lopinavir + ritonavir kienu l-simili (mhux inferjuri).
English: Atazanavir Cmax ↓31% (↓42%
Maltese: Cmax ta' Atazanavir ↓31% (↓42%
English: Four subjects in the unboosted atazanavir group and 2 in the atazanavir + ritonavir group had HIV RNA > 500 copies/ml during the maintenance phase.
Maltese: Erba' individwi fil-grupp ta' atazanavir mhux imsaħħaħ u 2 fil-grupp ta' atazanavir + ritonavir kellhom HIV RNA > 500 kopja/ml matul il-fażi ta' manutenzjoni.
English: Famotidine 40 mg twice daily Atazanavir AUC ↓24% (↓36%
Maltese: Atazanavir, iddożat siegħa wara ddI+d4T (fi stat sajjem) AUC ta' Atazanavir ↔3% (↓36%
English: Rare (may affect up to 1 in 1,000 people):
Maltese: Rari (jistgħu jaffettwaw sa persuna 1 minn kull 1,000):
English: Atazanavir Mylan 200 mg hard capsules
Maltese: Atazanavir Mylan 200 mg kapsuli ibsin
English: Capsules/ritonavir (300 mg/100 mg once daily) n=25
Maltese: ATV/RTVb (300 mg/ 100 mg darba kuljum) n=120
English: In HIV-infected patients (n=13), multiple dosing of atazanavir 400 mg (without ritonavir) once daily with food produced a geometric mean (CV%) for atazanavir Cmax of 2298 (71) ng/ml, with time to Cmax of approximately 2.0 hours.
Maltese: F'pazjenti infettati bl-HIV (n=13), l-għoti ta' dożi multipli ta' atazanavir 400 mg (mingħajr ritonavir) darba kuljum mal-ikel wassal għal medja ġeometrika (CV%) għas-Cmax ta' atazanavir ta' 2,298 (71) ng/ml, b'ħin ta' madwar sagħtejn għas-Cmax.
English: In some patients additional factor VIII was given.
Maltese: Xi pazjenti ngħataw fattur VIII addizzjonali.
English: The increase in progestin exposure may lead to related side-effects (e.g. insulin resistance, dyslipidemia, acne and spotting), thus possibly affecting the compliance.
Maltese: Iż-żieda fl-espożizzjoni ta' progestin tista' twassal għal effetti sekondarji relatati (eż. reżistenza għall-insulina, dislipidemija, akne u tikek fuq il-ġilda), b'hekk possibbilment tista' taffettwa lkonformità.
English: The mechanism of interaction is CYP3A4 inhibition by atazanavir and/or ritonavir.
Maltese: Il-mekkaniżmu ta' interazzjoni huwa l-inibizzjoni ta' CYP3A4 minn atazanavir u/jew ritonavir
English: Studies conducted in HIV-infected patients.
Maltese: Studji mwettqa fuq pazjenti infettati bl-HIV.
English: The mechanism of nevirapine/atazanavir interaction is CYP3A4 induction.
Maltese: Il-mekkaniżmu ta' interazzjoni ta' nevirapine/atazanavir huwa linduzzjoni ta' CYP3A4.
English: OPA/Aluminium/PVC - Aluminium blisters containing 60, 60 x 1 (unit dose) capsules.
Maltese: OPA/Aluminju/PVC - Folji tal-aluminju li jkun fihom 60, 60 x 1 (doża waħda) kapsula.
English: It is normally used in combination with other anti-HIV medicines.
Maltese: Normalment jintuża flimkien ma' mediċini oħra li jaħdmu kontra l-HIV.
English: In HIV-infected adult patients (n=33, combined studies) the mean half-life within a dosing interval for atazanavir was 12 hours at steady state following a dose of 300 mg daily with ritonavir 100 mg once daily with a light meal.
Maltese: F'pazjenti adulti infettati bl-HIV (n=33, studji kombinati), il-half-life medju fi ħdan intervall ta' dożaġġ għal atazanavir kien ta' 12-il siegħa wara li l-pazjenti ngħataw doża ta' 300 mg kuljum ma' ritonavir 100 mg darba kuljum ma' ikla ħafifa.
English: Concomitant use of Atazanavir Mylan/ritonavir and fluticasone or other glucocorticoids that are metabolised by CYP3A4 is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects, including Cushing's syndrome and adrenal suppression (see section 4.5).
Maltese: L-użu flimkien ta' Atazanavir Mylan/ritonavir u fluticasone jew glucocorticoids oħra li huma metabolizzati b'CYP3A4 mhux rakkomandat sakemm il-benefiċċju mistenni ma jkunx akbar mirriskju ta' l-effetti sistematiċi ta' corticosteroid, inkluż is-sindrome ta' Cushing u t-trażżin adrenali (ara sezzjoni 4.5).
English: Ethinyloestradiol Cmin ↓37% (↓45%
Maltese: Cmin ta' Ethinyloestradiol ↓37%
English: Ritonavir capsules, tablets or oral solution.
Maltese: 100 mg a Kapsuli, pilloli jew soluzzjoni orali ta' ritonavir.
English: Co-administration of lurasidone with atazanavir is contraindicated as this may increase lurasidone-related toxicity (see section 4.3).
Maltese: L-għoti flimkien ta' lurasidone ma' atazanavir huwa kontra-indikat għaliex dan jista' jżid it-tossiċità relatata ma' lurasidone (ara sezzjoni 4.3).
English: Ethinyloestradiol Cmax ↓16% (↓26%
Maltese: Cmax ta' Ethinyloestradiol ↓16%
English: When co-administered with tenofovir disoproxil fumarate, it is recommended that atazanavir 300 mg be given with ritonavir 100 mg and tenofovir disoproxil fumarate 300 mg (all as a single dose with food).
Maltese: Meta jingħata flimkien ma' tenofovir disoproxil fumarate, huwa rakkomandat li atazanavir 300 mg jingħata ma' ritonavir 100 mg u tenofovir disoproxil fumarate 300 mg (kollha bħala doża unika mal-ikel).
English: V.J.
Maltese: U L-UŻU C.
English: Resistance
Maltese: ANTIEPILETTIĊI
English: - in patients without a functional CYP2C19 allele, close clinical and laboratory monitoring of voriconazole-associated adverse events is recommended
Maltese: - f'pazjenti mingħajr allele CYP2C19 funzjonali, monitoraġġ kliniku u tal-laboratorju mill-qrib ta' każijiet avversi assoċjati ma' voriconazole hu rakkomandat.